Scale, Scope and Spillovers: The Determinants of Research Productivity in the Pharmaceutical Industry
57 Pages Posted: 29 Jun 2004 Last revised: 20 Sep 2014
Date Written: September 1993
Abstract
This paper presents the results of a study of the determinants of research productivity in the pharmaceutical industry. Using disaggregated, internal firm data at the research program level from ten major pharmaceutical companies, we find no evidence of increasing returns to scale at either the firm or the research program level. However our results suggest that there are three benefits to running research programs within the context of larger and more diversified R&D efforts: economies of scale arising from sharing fixed costs; economies of scope arising from the opportunity to exploit knowledge across program boundaries within the firm; and the enhanced ability to absorb internal and external spillovers. We also find that spillovers between firms may playa major role in increasing research productivity. The paper also speaks directly to the question of firm heterogeneity. A significant proportion of the "firm effect" identified in previous studies can be explained by the slowly changing composition of the research portfolio, as well as by less easily measured aspects of innovative capability.
Suggested Citation: Suggested Citation
Here is the Coronavirus
related research on SSRN
Paper statistics
Recommended Papers
-
Internal and External R&D: A Sample Selection Approach
By Claudio A. Piga and Marco Vivarelli
-
The Impact of Financial Constraints on Innovation: What Can Be Learned from a Direct Measure?
-
How Rapidly Does Science Leak Out?
By James D. Adams, Roger Clemmons, ...
-
Network Positioning and R&D Activity: A Study of Italian Groups
By Igor Filatotchev, Claudio A. Piga, ...
-
Financing New Investments Under Asymmetric Information: A General Approach
By Robin Boadway and Michael Keen
-
Financing Conditions, the Concept of Innovation Capacity and the Innovative Activity of Firms
By Georg Paula
-
Testing the Schumpeterian Hypotheses on an Open Innovation Framework
